Stefan Bernstein explains how the EU/Greenland critical raw materials partnership benefits GreenRoc. Watch the full video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
I would say it's a buy, but not particularly fussed
If they are giving 1.29 for 500k for a larger sell then could suggest some behind-the-scenes demand. Maybe Peter Sargent after a few million (joke)
Current price range is 1.23 -1.33 for modest amounts
Weather i say its a sell ,or a buy ,its what i see ...i'm sure your all old enough to make your own judgements ,so misleading is not my game...i see it how i see it ...you want to see another way feel free..,volume and price go hand in hand ,that information i'll give you for free
In the recent presentation, JM touched on the development of the PYC precision dosing tool to predict GCSF levels (currently subject to Innovate-funded trials involving Beyond Blood/Blackpool Hospital) and also mentioned that they were in discussions with Dosemerx to see whether there may be 'some way to work with them to gather more data'
I get a feeling that both Dosemerx and PYC see good potential here
Since the buy (500k)
Its now £1500 = 1.32p
£4000 = 1.35p
The 500k buy is why it's now 1 32p to buy as opposed to 1.29p at the start of the day
It's a buy msuk all 1.27p and 1.29p this week are buys
Please don't mislead
PYC now showing 'X' link to Dosemerx Precision Dosing article with this additional comment :-
'we're proud to be working alongside @DoseMeApp in advancing this field, leveraging mathematical modelling and clinical decision support software to tailor drug dosages and improve treatment outcomes for cancer patients'
I feel that we should get a decent update on progress with the Dosemerx partnership over the next few months
Interesting.
Dose me posted on twitter on 18th March, Pyc retweeted mentioning they still working with Doseme. I’m awaiting outcome of this.
https://x.com/Physiomics/status/1772939227359007009?s=20
https://x.com/Physiomics/status/1772939225266065552?s=20
Interesting you say its a sell as through Barclays the sells are at 1.23 and the buys are sub 1.333 for £100 dummy buy .. so not sure how someone got 1.29 on a 500K sell ..
Its a sell
500K buy gone through as a sell
They've been showing buys as sells (1.29p) amd tiny trades for days and werks now ..not sure why sorry
Spoke too soon. Why would someone buy £5.00 worth @ 1.40 ?
Never quite understood why market makers are prone to exaggerate the true bid-offer range. Clearly the current range here is around 1.21-1.29 and not 1.20-1.40 , as shown
Are they trying to dissuade buyers for some reason or is it just laziness on their part. Surely they are depressing interest and potentially losing some commission as a result
I assume SAR who have raised and spent £20mln+and already had 2 share consolidation and who's directors get paid £200k+!!
Wrong BB - apologies all !
Many on here said they would subscribe to a placing when the SP was at 25p ... and now it is at 14p and still nothing !!!!
Do they have a plan which does not consider shareholder value ?? ... for instance moving compounds and jobs to a new company, looking after themselves but not the shareholders ??
Have to say I am imagining dodgy dealings behind the scenes which are solely aimed at the BOD looking after themselves
Hope I am wrong !
Ýeah Truro
Another really impressive overview by Peter
Only caught up to the presentation today. Very impressed by the way Peter Sargent is working ON the business. There seems to be a real improvement in the structure and oversight. Bodes very well for the future - particularly the two newer parts that are yet to produce revenue. Good times ahead I think!
Apologies
2/3
All 3 small trades were buys too yesterday
Because at the time it was made (and reporting delayed) it was 1.21 sell and 1.27p buy
Are you referring to the 600k trade? How do we know it was a buy?
Could it be Peter has dipped his hands in his pockets?
This month the Physiomics team attended the 14th Annual World ADC Event in London on 13th and 14th of March 2024, Europe’s definitive Antibody-Drug Conjugate meeting, attended by 600+ experts from the field. It was a great event to meet with leaders of the field and learn about the trends and lessons in this exciting and growing industry. In particular to discuss where quantitative pharmacology and PK/PD modelling expertise can help to inform and de-risk development, in areas such as;
Discovery:
Model impact of ADC design, including properties such as binding affinity to target, payload release rate, elimination rate, half-life, DAR etc. on payload delivery to the tumour, to inform selection of your lead candidate
Pre-clinical/Translation:
Predict human PK & PD to select FIH dose and understand optimal dose range in the clinic
Clinical development;
Understand exposure-response relationships in both safety and efficacy for all components of the ADC (total antibody, ADC, free payload)
Alter dosing schedule to reduce toxicity
Define dosing strategies for specific patient populations or sub-groups
For more information on the clinical pharmacology considerations for development of ADC’s, see the Guidance for Industry issued by the FDA’s Center for Drug Evaluation and Research or discuss with the team at Physiomics!
Largest buy for a while